Accelerating Medicines Partnership® Parkinson's Disease

The Accelerating Medicines Partnership – Parkinson’s Disease (AMP PD) is a public-private partnership formed for the purpose of identifying and validating diagnostic, prognostic, and progression biomarkers for Parkinson’s Disease. To accomplish this goal, AMP PD harmonized longitudinal clinical data from seven large existing cohorts and conducted whole genome sequencing, longitudinal transcriptomics, and longitudinal proteomics analyses from their existing blood, CSF, and/or brain tissue samples. AMP PD data, along with the federated, international Global Parkinson’s Genetics Program (GP2) data, exists in the Google Cloud and is accessible and analyzable on the Verily/Broad Institute’s Terra Platform.

加速药物合作项目-帕金森病（AMP PD）是一项旨在识别并验证帕金森病诊断性、预后性及疾病进展相关生物标志物的公私合作伙伴关系。为达成这一目标，该项目对7个大型现有队列的纵向临床数据进行了标准化整合，并针对其现有的血液、脑脊液（Cerebrospinal Fluid，简称CSF）和/或脑组织样本开展了全基因组测序、纵向转录组学及纵向蛋白质组学分析。AMP PD数据集与具备联邦式数据架构的国际全球帕金森病遗传学项目（GP2）的数据集均托管于谷歌云（Google Cloud），并可在Verily与博德研究所联合打造的Terra平台上实现访问与分析。

搜集汇总

背景与挑战

背景概述

AMP PD是一个公私合作项目，旨在识别和验证帕金森病的生物标志物。该项目整合了多个队列的纵向临床数据，并进行了全基因组测序、转录组学和蛋白质组学分析，数据可通过Google Cloud和Terra平台访问与分析。